• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全基因组 CRISPR 筛选确定了胰腺癌细胞介导的上皮-间充质转化免疫逃逸的决定因素。

Genome-wide CRISPR screens define determinants of epithelial-mesenchymal transition mediated immune evasion by pancreatic cancer cells.

机构信息

Oncode Institute and Department of Cell and Chemical Biology, Leiden University Medical Center, Einthovenweg 20, 2333 ZC Leiden, Netherlands.

Institutes of Biology and Medical Science, Soochow University, Suzhou 215123, China.

出版信息

Sci Adv. 2023 Jul 14;9(28):eadf9915. doi: 10.1126/sciadv.adf9915.

DOI:10.1126/sciadv.adf9915
PMID:37450593
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10348683/
Abstract

The genetic circuits that allow cancer cells to evade immune killing via epithelial mesenchymal plasticity remain poorly understood. Here, we showed that mesenchymal-like (Mes) KPC3 pancreatic cancer cells were more resistant to cytotoxic T lymphocyte (CTL)-mediated killing than the parental epithelial-like (Epi) cells and used parallel genome-wide CRISPR screens to assess the molecular underpinnings of this difference. Core CTL-evasion genes (such as IFN-γ pathway components) were clearly evident in both types. Moreover, we identified and validated multiple Mes-specific regulators of cytotoxicity, such as Egfr and Mfge8. Both genes were significantly higher expressed in Mes cancer cells, and their depletion sensitized Mes cancer cells to CTL-mediated killing. Notably, Mes cancer cells secreted more Mfge8 to inhibit proliferation of CD8 T cells and production of IFN-γ and TNFα. Clinically, increased Egfr and Mfge8 expression was correlated with a worse prognosis. Thus, Mes cancer cells use Egfr-mediated intrinsic and Mfge8-mediated extrinsic mechanisms to facilitate immune escape from CD8 T cells.

摘要

癌症细胞通过上皮间质可塑性逃避免疫杀伤的遗传回路仍然知之甚少。在这里,我们表明,间充质样(Mes)KPC3 胰腺癌细胞比亲本上皮样(Epi)细胞更能抵抗细胞毒性 T 淋巴细胞(CTL)介导的杀伤,并用平行的全基因组 CRISPR 筛选来评估这种差异的分子基础。核心 CTL 逃逸基因(如 IFN-γ 途径成分)在这两种类型中都很明显。此外,我们鉴定并验证了多个细胞毒性的 Mes 特异性调节剂,如 Egfr 和 Mfge8。这两个基因在 Mes 癌细胞中的表达明显更高,其耗竭使 Mes 癌细胞对 CTL 介导的杀伤敏感。值得注意的是,Mes 癌细胞分泌更多的 Mfge8 来抑制 CD8 T 细胞的增殖以及 IFN-γ 和 TNFα 的产生。临床上,Egfr 和 Mfge8 表达的增加与预后不良相关。因此,Mes 癌细胞利用 Egfr 介导的内在机制和 Mfge8 介导的外在机制来促进对 CD8 T 细胞的免疫逃逸。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5daf/10348683/3787d0ac902b/sciadv.adf9915-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5daf/10348683/ac11ec9874ae/sciadv.adf9915-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5daf/10348683/f1c88714280a/sciadv.adf9915-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5daf/10348683/03fb3a1a636b/sciadv.adf9915-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5daf/10348683/95e25c43f314/sciadv.adf9915-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5daf/10348683/e2e091689ebb/sciadv.adf9915-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5daf/10348683/b841293911b2/sciadv.adf9915-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5daf/10348683/3787d0ac902b/sciadv.adf9915-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5daf/10348683/ac11ec9874ae/sciadv.adf9915-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5daf/10348683/f1c88714280a/sciadv.adf9915-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5daf/10348683/03fb3a1a636b/sciadv.adf9915-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5daf/10348683/95e25c43f314/sciadv.adf9915-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5daf/10348683/e2e091689ebb/sciadv.adf9915-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5daf/10348683/b841293911b2/sciadv.adf9915-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5daf/10348683/3787d0ac902b/sciadv.adf9915-f7.jpg

相似文献

1
Genome-wide CRISPR screens define determinants of epithelial-mesenchymal transition mediated immune evasion by pancreatic cancer cells.全基因组 CRISPR 筛选确定了胰腺癌细胞介导的上皮-间充质转化免疫逃逸的决定因素。
Sci Adv. 2023 Jul 14;9(28):eadf9915. doi: 10.1126/sciadv.adf9915.
2
Complementary CRISPR screen highlights the contrasting role of membrane-bound and soluble ICAM-1 in regulating antigen-specific tumor cell killing by cytotoxic T cells.互补性 CRISPR 筛选突出了膜结合型和可溶性 ICAM-1 在调节细胞毒性 T 细胞对肿瘤抗原特异性杀伤中的相反作用。
Elife. 2023 Sep 21;12:e84314. doi: 10.7554/eLife.84314.
3
Functional genomic landscape of cancer-intrinsic evasion of killing by T cells.肿瘤细胞内在逃避 T 细胞杀伤的功能基因组景观
Nature. 2020 Oct;586(7827):120-126. doi: 10.1038/s41586-020-2746-2. Epub 2020 Sep 23.
4
Tumor immune evasion arises through loss of TNF sensitivity.肿瘤免疫逃逸是通过 TNF 敏感性丧失而产生的。
Sci Immunol. 2018 May 18;3(23). doi: 10.1126/sciimmunol.aar3451.
5
In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer.在体 CRISPR 筛选揭示了癌症中免疫逃逸途径的全景。
Nat Immunol. 2022 Oct;23(10):1495-1506. doi: 10.1038/s41590-022-01315-x. Epub 2022 Sep 23.
6
A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity.CRISPR 激活筛选确定 MUC-21 对于抵抗 NK 和 T 细胞介导的细胞毒性至关重要。
J Exp Clin Cancer Res. 2023 Oct 20;42(1):272. doi: 10.1186/s13046-023-02840-9.
7
Cancer cell-intrinsic resistance to BiTE therapy is mediated by loss of CD58 costimulation and modulation of the extrinsic apoptotic pathway.肿瘤细胞内在抵抗 BiTE 治疗是由 CD58 共刺激的缺失和外在凋亡途径的调节介导的。
J Immunother Cancer. 2022 Mar;10(3). doi: 10.1136/jitc-2021-004348.
8
Computational Discovery of Cancer Immunotherapy Targets by Intercellular CRISPR Screens.细胞间 CRISPR 筛选发现癌症免疫治疗靶点
Front Immunol. 2022 May 16;13:884561. doi: 10.3389/fimmu.2022.884561. eCollection 2022.
9
A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing.高通量免疫肿瘤学筛选鉴定出 EGFR 抑制剂作为增强抗原特异性细胞毒性 T 淋巴细胞杀伤肿瘤细胞的有效增强剂。
Cancer Immunol Res. 2018 Dec;6(12):1511-1523. doi: 10.1158/2326-6066.CIR-18-0193. Epub 2018 Sep 21.
10
PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.程序性死亡受体配体1(PD-L1)表达与肺腺癌的上皮-间质转化相关。
Hum Pathol. 2016 Dec;58:7-14. doi: 10.1016/j.humpath.2016.07.007. Epub 2016 Jul 26.

引用本文的文献

1
CRISPR/Cas technologies in pancreatic cancer research and therapeutics: recent advances and future outlook.CRISPR/Cas技术在胰腺癌研究与治疗中的应用:最新进展与未来展望
Discov Oncol. 2025 Aug 11;16(1):1530. doi: 10.1007/s12672-025-03383-5.
2
Advancements in CRISPR/Cas systems for disease treatment.用于疾病治疗的CRISPR/Cas系统的进展。
Acta Pharm Sin B. 2025 Jun;15(6):2818-2844. doi: 10.1016/j.apsb.2025.05.007. Epub 2025 May 17.
3
ERK2-mediated phosphorylation of ZEB1 at S322 enhances PD-L1 expression and EMT, leading to pancreatic cancer progression.

本文引用的文献

1
EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer.EGFR 是炎性乳腺癌中免疫抑制和免疫激活肿瘤微环境之间的主开关。
Sci Adv. 2022 Dec 16;8(50):eabn7983. doi: 10.1126/sciadv.abn7983.
2
In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer.在体 CRISPR 筛选揭示了癌症中免疫逃逸途径的全景。
Nat Immunol. 2022 Oct;23(10):1495-1506. doi: 10.1038/s41590-022-01315-x. Epub 2022 Sep 23.
3
RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells.
细胞外信号调节激酶2(ERK2)介导的锌指E盒结合蛋白1(ZEB1)第322位丝氨酸磷酸化增强程序性死亡受体配体1(PD-L1)表达并促进上皮-间质转化(EMT),从而导致胰腺癌进展。
Cell Commun Signal. 2025 Apr 28;23(1):204. doi: 10.1186/s12964-025-02182-3.
4
Epithelial-mesenchymal transition orchestrates tumor microenvironment: current perceptions and challenges.上皮-间质转化调控肿瘤微环境:当前认知与挑战
J Transl Med. 2025 Apr 2;23(1):386. doi: 10.1186/s12967-025-06422-5.
5
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment.癌症治疗中使免疫检查点抑制剂致敏的当前趋势。
Mol Cancer. 2024 Dec 26;23(1):279. doi: 10.1186/s12943-024-02179-5.
6
High-throughput screening for optimizing adoptive T cell therapies.用于优化过继性T细胞疗法的高通量筛选
Exp Hematol Oncol. 2024 Nov 13;13(1):113. doi: 10.1186/s40164-024-00580-w.
7
GHRH-stimulated pituitary small extracellular vesicles inhibit hepatocyte proliferation and IGF-1 expression by its cargo miR-375-3p.生长激素释放激素刺激垂体小细胞外囊泡通过其货物 miR-375-3p 抑制肝细胞增殖和 IGF-1 表达。
J Nanobiotechnology. 2024 Oct 22;22(1):649. doi: 10.1186/s12951-024-02857-y.
8
Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma.肿瘤细胞可塑性决定了皮肤鳞状细胞癌对免疫治疗的反应。
Nat Commun. 2024 Jun 24;15(1):5352. doi: 10.1038/s41467-024-49718-8.
9
Current and future immunotherapeutic approaches in pancreatic cancer treatment.当前和未来在胰腺癌治疗中的免疫治疗方法。
J Hematol Oncol. 2024 Jun 4;17(1):40. doi: 10.1186/s13045-024-01561-6.
10
Targeting the deubiquitinase for malignant tumor therapy (Review).靶向去泛素化酶治疗恶性肿瘤(综述)。
Oncol Rep. 2023 Oct;50(4). doi: 10.3892/or.2023.8613. Epub 2023 Aug 18.
RNF31 抑制使肿瘤对先天和适应性免疫细胞的旁观者杀伤敏感。
Cell Rep Med. 2022 Jun 21;3(6):100655. doi: 10.1016/j.xcrm.2022.100655. Epub 2022 Jun 9.
4
Dynamic Visualization of TGF-β/SMAD3 Transcriptional Responses in Single Living Cells.单个活细胞中TGF-β/SMAD3转录反应的动态可视化
Cancers (Basel). 2022 May 19;14(10):2508. doi: 10.3390/cancers14102508.
5
Resistance Mechanisms to Anti-PD Cancer Immunotherapy.抗 PD 癌症免疫疗法的耐药机制。
Annu Rev Immunol. 2022 Apr 26;40:45-74. doi: 10.1146/annurev-immunol-070621-030155.
6
Loss of Rnf31 and Vps4b sensitizes pancreatic cancer to T cell-mediated killing.Rnf31 和 Vps4b 的缺失使胰腺癌对 T 细胞介导的杀伤敏感。
Nat Commun. 2022 Apr 4;13(1):1804. doi: 10.1038/s41467-022-29412-3.
7
Epithelial-Mesenchymal Plasticity in Tumor Immune Evasion.肿瘤免疫逃逸中的上皮-间充质可塑性。
Cancer Res. 2022 Jul 5;82(13):2329-2343. doi: 10.1158/0008-5472.CAN-21-4370.
8
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer.LCOR 介导三阴性乳腺癌中干扰素非依赖性肿瘤免疫原性和对免疫检查点阻断的反应性。
Nat Cancer. 2022 Mar;3(3):355-370. doi: 10.1038/s43018-022-00339-4. Epub 2022 Mar 17.
9
ZEB1 transcription factor promotes immune escape in melanoma.ZEB1 转录因子促进黑色素瘤的免疫逃逸。
J Immunother Cancer. 2022 Mar;10(3). doi: 10.1136/jitc-2021-003484.
10
Mechanisms of immune activation and regulation: lessons from melanoma.免疫激活和调节的机制:黑色素瘤的启示。
Nat Rev Cancer. 2022 Apr;22(4):195-207. doi: 10.1038/s41568-022-00442-9. Epub 2022 Feb 1.